This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siddiqi, A. Articles by Monson, J. P. Search for Related Content PubMed PubMed Citation Articles by Siddiqi, A. Articles by Monson, J. P.

A Longitudinal Study of Markers of Bone Turnover in Graves’ Disease and Their Value in Predicting Bone Mineral Density

Departments of Endocrinology (A.S., I.J., D.F.W., J.P.M.) and Clinical Biochemistry (A.S., J.M.B., K.N., C.P.P.), St. Bartholomew’s and the Royal London Hospital, London E1 1BB, England

Address all correspondence and requests for reprints to: Dr. A. Siddiqi, Department of Metabolism and Endocrinology, Alexandra Wing, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, Whitechapel, London E1 1BB, England. E-mail: ASiddiqi{at}mds.qmw.ac.uk

Whether biochemical markers can predict improvement in reduced bone mineral density (BMD) associated with thyrotoxicosis is unclear. We investigated the relationship between serum osteocalcin (OC), bone-specific alkaline phosphatase (b-ALP), serum deoxypyridinoline (Sdpd) and pyridinoline (Spyr), 24-hour urinary deoxypyridinoline (Udpd), and BMD in 17 thyrotoxic patients during 1 yr of treatment.

Coinciding with euthyroidism at 4–8 weeks, there was a peak in b-ALP and OC and a prompt fall into the normal range in Udpd and Sdpd, but not Spyr, levels. Mean b-ALP continued to be raised at week 52 when it was inversely correlated with BMD. Mean BMD rose approximately 6%, P < 0.01, over 1 yr. Coupling indices were calculated as a measure of bone balance and, at diagnosis, was [minus4.26 in favor of bone resorption and rose with treatment in favor of bone formation: weeks 2: -0.23; 4: +4.01; 8: +4.37; 12: +4.44; 24: +2.32; and 52: +1.56.

Bone turnover is balanced within 2 weeks of starting treatment for thyrotoxicosis. Udpd accurately indicates thyrotoxic bone resorption. Serum b-ALP indicates continuing bone formation and, at 1 yr, may provide a marker for low BMD. OC, Sdpd, and Spyr are less sensitive in documenting bone remodeling during treatment of thyrotoxicosis.

This article has been cited by other articles:

				S. J. Hoffman, J. Vasko-Moser, W. H. Miller, M. W. Lark, M. Gowen, and G. Stroup Rapid Inhibition of Thyroxine-Induced Bone Resorption in the Rat by an Orally Active Vitronectin Receptor Antagonist J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 205 - 211. [Abstract] [Full Text] [PDF]

				A. Siddiqi, M. P. Parsons, J. L. Lewis, J. P. Monson, G. R. Williams, and J. M. Burrin TR Expression and Function in Human Bone Marrow Stromal and Osteoblast-Like Cells J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 906 - 914. [Abstract] [Full Text] [PDF]

				H. W. Vesper, L. M. Demers, R. Eastell, P. Garnero, M. Kleerekoper, S. P. Robins, A. K. Srivastava, G. R. Warnick, N. B. Watts, and G. L. Myers Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline Clin. Chem., February 1, 2002; 48(2): 220 - 235. [Abstract] [Full Text] [PDF]

				H. Pantazi and P. D. Papapetrou Changes in Parameters of Bone and Mineral Metabolism during Therapy for Hyperthyroidism J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1099 - 1106. [Abstract] [Full Text]

				A. Siddiqi, J. P. Monson, D. F. Wood, G. M. Besser, and J. M. Burrin Serum Cytokines in Thyrotoxicosis J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 435 - 439. [Abstract] [Full Text]